Canaccord Genuity Maintains Buy on Neuronetics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on Neuronetics (NASDAQ:STIM) but lowers the price target from $6 to $3.
August 13, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Canaccord Genuity analyst William Plovanic maintains a Buy rating on Neuronetics but lowers the price target from $6 to $3.
The lowered price target from $6 to $3 indicates a less optimistic outlook for Neuronetics, which could negatively impact short-term investor sentiment despite the maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100